News Hub | News Direct

PathAI Announces IBD Explore, an AI-powered Histopathology Panel to Unlock Insights for Ulcerative Colitis from the Inflammatory Microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of IBD Explore 1, an artificial intelligence-powered panel of human interpretable features (HIFs) offering unprecedented resolution of the inflammatory microenvironment from H&E whole-slide images. IBD Explore uses more than 600 histopathology features to spatially characterize the inflammatory microenvironment, giving drug developers and clinical researchers the ability to unlock insights to inform the next phase of targeted drug development in ulcerative colitis (UC). According to the Centers for Disease Control (CDC), an increasing number of American adults have faced diagnosis of either UC or Crohn’s disease, known collectively as Inflammatory bowel disease (IBD) over the past two decades. Over the past few decades the global prevalence of UC and Crohn's disease, known collectively as inflammatory bowel disease (IBD) has increased. A Lancet study 2 found that the prevalence increased from 1990 with 79.5 per 100,000 population with IBD to 84.3 per 100,000 population in 2017. Despite this, remission rates for UC drugs have not surpassed 30% 3 and more than 30% of UC patients stop biologic therapy within 12-18 months due to lack or loss of efficacy. 4 These observations underscore the need for biomarkers such as histologic signatures to aid in drug development and patient management. Previous research found histologic measures of response to be a better predictor of drug efficacy for relapse-free survival in UC patients than endoscopy alone. 5 IBD Explore allows researchers enhanced histologic visibility, with the ability to structure and analyze spatial measures on a scalable platform, allowing insights to inform future trials. “IBD Explore provides visibility down to each individual cell in the inflammatory tissue environment and HIFs, and a level of granularity that we’ve never had,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “This level of detail helps researchers identify patient subtypes and develop customized therapeutics with the hopes of greater efficacy and increased remission for UC patients.” In addition to IBD Explore, PathAI also offers automated, AI-powered Geboes scoring with its tool AI Measurement of Histological Index for Ulcerative Colitis, or AIM-HI™UC. Combined, IBD Explore and AIM-HI UC provide IBD drug developers a complete histology solution for translational research and clinical development. “The utilization of AI-powered pathology has the potential to tremendously benefit researchers in drug discovery and clinical development by reducing trial risk and enhancing therapy differentiation,” said Mike Montalto, Ph.D., chief scientific officer at PathAI. “Our suite of AI-powered solutions can reduce the noise in histological-based endpoints for IBD clinical trials and therefore isolate true drug effect. In collaboration with our biopharma partners, we aim to accelerate precision medicine options for millions of patients with UC.” To learn more about IBD Explore, visit www.IBDExplore.com Footnotes 1 IBD Explore is for research use only. Not for use in diagnostic procedures. 2 The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. October 2020. | https://doi.org/10.1016/S2468-1253(19)30333-4 3 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 4 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 5 Breaking the therapeutic ceiling in drug development in ulcerative colitis. May 2021. | https://doi.org/10.1016/S2468-1253(21)00065-0 About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to be a rapidly expanding organization comprised of innovative thinkers from around the globe, For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

May 17, 2023 10:00 AM Eastern Daylight Time

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program

Immunic Inc

Immunic Inc president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming that vidofludimus calcium (IMU-838) acts as a potent nuclear receptor-related 1 (Nurr1) activator, in addition to its known mode of action as a dihydroorotate dehydrogenase (DHODH) inhibitor. Vitt said described it as another exciting milestone for Immunic's lead development program as it suggests that Nurr1 may be responsible for the drug’s postulated neuroprotective effects. The company has also taken steps to strengthen its intellectual property position with the submission of a new patent application in the United States and European Union, he added. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2023 10:00 AM Eastern Daylight Time

Video

Ergomed in robust shape to keep delivering

Ergomed PLC

Jonathan Curtain, the new CFO of Ergomed, discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and oncology. Curtain brings extensive experience in finance and investor relations from his previous role as Senior Vice President of Finance at NASDAQ-listed CRO, Icon PLC. With strong financial results in 2022, showing revenue growth of 23% and an increased order book, Curtain expressed confidence in Ergomed's ability to deliver and execute projects, and highlighted their positive outlook for mergers and acquisitions to further strengthen their services. Despite industry headwinds, the company remains optimistic about its future prospects. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2023 08:59 AM Eastern Daylight Time

Video

Singaporean Telehealth Platform ORA Raises $10 Million Series A to Modernise Healthcare in the Region

ORA

Singaporean telehealth platform ORA has raised a $10 million USD Series A funding. This is the largest telehealth Series A in South-East Asia and was co-led by TNB Aura and Antler with participation from Gobi Partners, Kairous Capital and GMA Ventures, bringing total funding to date above $17 million USD. ORA is the fastest-growing and biggest vertically-integrated telehealth platform in South East Asia delivering over 250,000 consultations and has experienced uninterrupted monthly growth since its 2021 launch. ORA has launched three brands that serve the modern patient living with chronic conditions, making treatment more accessible, convenient and personal. Modules is a first to market online dermatology experience making personalised, prescription skincare accessible with 676 different formulations, andSons offers male health solutions and OVA delivers female reproductive healthcare. Founded by former ZALORA CMO Elias Pour, ORA is uniquely positioned with a diverse, proven leadership team with rich backgrounds across health, tech and consumer brands. Backed by a robust medical advisory board, ORA’s R&D team draws on experience from L’Oréal and Sephora creating high-touch products and experiences that are IP’d and 100% in-house developed. With a strong attention to customer experience, first to market solutions like Modules, andSons and Ova are meeting modern customer expectations head on. These interactions are translating into deeper patient relationships, building retention rates only rivalled by subscription models like Netflix and unrivalled within the industry. 90% of ORA’s patients are first to condition, under 38 years old and have never been treated before. The disconnect between this younger patient population and the traditional healthcare model is ORA’s biggest opportunity. These new patients have a different set of demands such as flexibility and speed which ORA’s telemedicine model is perfectly placed to treat. ORA’s seamless end-to-end experience joins up the fragmented traditional model, linking consultation, education, pharmacy, delivery and post purchase care for unparalleled convenience. “ORA is on a mission to deliver high touch, high-quality care to millions of patients and with our continued growth story throughout SEA, we are thrilled with today's announcement.” said Elias Pour, ORA’s founder and CEO. “ORA has had over 6 million patient touch points provide us with valuable health data through extensive health evaluations and consultation online. This has brought unique insights into these patient’s healthcare expectations that has and will inform future innovations with our key partners.” “We have the high growth potential of DTC, with a very high percentage of healthcare expenditure in our region being out of pocket. This is powered by an underlying SAAS type of recurring revenue, with subscriptions counting for more than 70% of our revenue and our retention is better than Netflix with 10x the monthly order value. We achieved post marketing breakeven at the end of last year on a group level after just 20 months of going live and have a very clear and believable path to profitability that is imminently ahead of us. With this new round of funding ORA will seek to expand its presence into new territories, both geographically and with new offerings. Later this year ORA’s brands will arrive in retail across 1300 tier one stores bringing its accessible, medically-backed range of products to shelves. Looking at different geographies there are opportunities to expand into regions like the GCC. Charles Wong, Founding Partner at TNB Aura commented: “Since ORA’s early days, TNB Aura has been a firm believer and strong supporter of Elias and the ORA team in their unwavering mission to provide access to affordable high-quality healthcare. Their combined focus on specialised, and often taboo, healthcare verticals as well as a direct-to-patient approach has led the team to clearly differentiate itself while delivering market-leading unit economics that meet the tailored needs of patients across the full value chain.” Teddy Himler - Global Partner at Antler added: “Elias and team have learned from the extraordinary rise of telehealth globally and have applied it masterfully to the idiosyncratic (and often challenging) South East Asia region. We are inspired and supportive of their mission to become the “ Healthcare House of Brands” for the ~1B people in South East Asia and GCC who are underserved by the traditional healthcare system. We think ORA’s platform approach is the future of direct-to-patient healthcare globally.” About ORA ORA is a house of healthcare brands powered by a vertically integrated telehealth platform. Founded in 2020 by ex ZALORA CMO Elias Pour, it is now SEA’s fastest growing digital health provider operating in Singapore, Malaysia and the Philippines with additional markets being launched during the rest of 2023. Its growing portfolio of healthcare brands includes Modules (prescription skincare), OVA (women’s health) and andSons (men’s health). Their HQ is located in Singapore. About TNB Aura At TNB Aura, we are investing in and helping to build the future of Southeast Asia. As a thesis-led, high-conviction venture capital firm, we use data-driven methodologies to identify and invest in select companies that are primed for the future and ready to change the very face of their categories. An approved co-investment partner of Enterprise Singapore, we invest US$2-10 million into Series A and B tech startups - and beyond that, we become true partners in their quest to uplift lives of The Next Billion. About Antler Antler is the investor backing the world’s most driven founders from day zero to greatness. Founded on the belief that people innovating is the key to building a better future, we partner with people across six continents to launch and scale high-potential startups that address meaningful opportunities and challenges. Knowing that exceptional founders can come from anywhere with any background, we have offices in 25 cities, including Austin, New York, London, Berlin, Stockholm, Bangalore, Jakarta, Singapore, Seoul, Tokyo, and Sydney. Our global community backs people from the beginning with co-founder matching, deep business model validation, initial capital, expansion support, and follow-on funding. Fueled by a personal passion that goes beyond traditional investing, we have helped create and invested in more than 750 startups across a wide range of industries and technologies, with the goal of backing more than 6,000 by 2030. Contact Details ORA Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.ora.group/

May 17, 2023 07:00 AM Eastern Daylight Time

Image

Instem proves in step with groundbreaking market needs as it posts strong 2022 performance

Instem PLC

Phil Reason, CEO of Instem PLC, joined Proactive with details of the company's 2022 financial performance. The company grew revenues by 28% and underlying earnings were up 32%. It also said it expected to benefit in 2023 from ‘industry consolidation’. Recent success include increased recurring revenue and a renewed contract with the US government's National Toxicology Program. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2023 03:00 AM Eastern Daylight Time

Video

News Release

NuggMD Lowers Price of Medical Marijuana Evaluations to $99 to Celebrate Dispensary Openings in Georgia

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine provider, is celebrating the opening of the first two dispensaries in Georgia by temporarily lowering the price of medical marijuana evaluations in that state from $139 to $99. "Georgia is finally providing legal cannabis access for its nearly 30,000 medical marijuana patients," said Collin Mann, CEO and co-founder of NuggMD. "We're thrilled to support this effort by making our services more affordable for patients in the state." In April, the Georgia Access to Medical Cannabis Commission announced that it had awarded licenses to Truelieve and Botanical Sciences to cultivate and manufacture medical cannabis. Each company will be allowed to open up to six dispensaries. The first two of these new dispensaries are owned by Truelieve and located in Marietta and Macon. Botanical Sciences will open its first dispensaries in Marietta and Pooler in July. True to form, Truelieve will keep the competition hot by opening a dispensary in Pooler also. "The opening of dispensaries in Georgia is a major milestone for the state's medical marijuana program," said Kamran Babazade, COO and co-founder of NuggMD. "Now we have to make sure we remove the remaining barriers to treatment in these uncertain economic times." "Our goal is to make it as easy as possible for patients to get the care they need," said Alex Milligan, CMO and co-founder of NuggMD. "We are committed to ensuring patients have access to safe, legal, and affordable medical cannabis." NuggMD's telemedicine platform allows patients to connect with licensed medical marijuana doctors online, making it easy and convenient to get a medical marijuana evaluation. Evaluations are available seven days a week. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Georgia. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

May 16, 2023 01:41 PM Eastern Daylight Time

News Release

Vivos Therapeutics talks clinical study success of POD migraine treatment, new timeline for cashflow

Vivos Therapeutics

Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studio to discuss how the company's POD device performed a highly effective rate in treating migraine headaches in a clinical study. Huntsman says the study showed 92% of patients reporting complete resolution of their symptoms, which is an unprecedented result for a non-pharmaceutical application in this field. He adds that the device has potential for other applications, such as treating upper airway resistance, TMD, bruxism, and various pain conditions, but further research and FDA indications are required. Vivos Therapeutics has also reported an accelerated timeline for reaching positive cash flow. Huntsman says Vivos has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses, and positioning Vivos to take advantage of current growth opportunities. Now, the company projects it could hit the positive milestone at the beginning of 2024. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 16, 2023 01:19 PM Eastern Daylight Time

Video

Immunic Inc set to bring relief with encouraging results

Immunic Inc

Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive. The company presented positive data from a clinical trial at the Digestive Disease Week conference, showcasing the first clinical proof of concept for their molecule 856 in patients with celiac disease, targeting the renewal of the gut barrier function and tissue, eliminating the need for immunosuppressive effects. Additionally, the company has sufficient funding until the fourth quarter of 2024. Immunic expects first interim data from their phase two study in progressive MS later this year, further bolstering their overall MS strategy. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 16, 2023 01:07 PM Eastern Daylight Time

Video

Radius boosts Scientific Advisory Board with the introduction of nine world-class advisors

Radius

Radius XR ®, the wearable digital healthcare technology brand, has added nine leading physicians and thought leaders to its Scientific Advisory Board to provide strategic scientific guidance and an insightful, hands-on perspective on the challenges eyecare professionals face. “The members of our Scientific Advisory Board are the industry’s brightest and most innovative researchers and practitioners,” said Radius CEO Ammad Khan, “and they share a passion for using technology to provide unsurpassed eye care. Their world-class expertise and insights fuel our continued drive to help professionals provide unsurpassed glaucoma care with innovative products that deliver the highest level of clinical accuracy.” Nine medical professionals at the leading edge of research and treatment Iqbal "Ike" K. Ahmed, MD, FRCSC, directs the Alan S. Crandall Center for Glaucoma Innovation and oversees its surgical therapeutics initiative. A glaucoma, cataract, and anterior segment surgeon, Dr. Ahmed has since been recognized as one of the world’s top surgeons for complex eye conditions, repeatedly named among the most influential ophthalmologists worldwide by The Ophthalmologist magazine. He is renowned for conducting groundbreaking research and device development that has advanced the surgical treatment of diseases, including glaucoma and surgical complications. A pioneer in innovative glaucoma therapeutics who coined the term “micro-invasive glaucoma surgery” (MIGS), Dr. Ahmed has been the principal investigator for numerous research studies and served as a medical monitor for many pivotal clinical trials, including the first long-term outcomes study of a MIGS device. He has published over 170 peer-reviewed papers and several books and made over 1,000 scientific presentations, including 40 visiting professor lectures worldwide. He sits on the editorial boards of Ophthalmology, Ophthalmology-Glaucoma, Journal of Glaucoma, Canadian Journal of Ophthalmology, EyeNet, Ocular Surgery News, Cataract and Refractive Surgery Today, and is a reviewer for numerous journals. In 2018, Glaucoma Today appointed him as Chief Medical Editor. Dr. Ahmed has received multiple awards, including the prestigious American Society of Cataract and Refractive Surgery's Binkhorst medal. Jason Bacharach, MD, a glaucoma consultant since 1993, is Director of Research at North Bay Eye Associates, a multi-subspecialty eyecare practice. He is also co-chair of the Department of Glaucoma at California Pacific Medical Center in San Francisco. Dr. Bacharach has served as Principal Investigator in more than 200 phase I through IV clinical trials in ophthalmology, including pharmacology and device studies related to glaucoma management and numerous other ocular diseases. A Fellow of the American Glaucoma Society and Past Chair of the American Academy’s Ophthalmic Knowledge-Based Panel for Glaucoma, Dr. Bacharach has twice been honored by the American Academy of Ophthalmology, receiving the Achievement Award in 2005 and the Secretariat Award in 2013. He travels the world extensively to lecture and has authored many articles in peer-reviewed literature and book chapters. Howard Barnebey, MD, founder of Specialty Eyecarè Centre, is one of only a few ophthalmologists in the northwest U.S. who is a cataract surgeon trained in the subspecialty of interventional ophthalmology. Throughout his career, he has remained committed to education, advancing medical innovation, and to expanding biomedical eye research. Dr. Barnebey served as a clinical assistant professor at the University of Washington, teaching residents for over 20 years, and has been a leading contributor to ophthalmology since the early 1980s, publishing articles in major medical journals. Mile Brujic, OD, FAAO, is a 2002 New England College of Optometry graduate. He is a partner of Premier Vision Group, a successful four-location optometric practice in Northwest Ohio. He practices full-scope optometry, emphasizing ocular disease management of the anterior segment, specialty contact lenses, and glaucoma. He is active at all levels of organized optometry. Dr. Brujic is on the editorial board for several optometric publications. He has published over 400 articles and given over 2000 lectures nationally and internationally on contemporary topics in eye care. April Jasper, OD, owns Advanced Eyecare Specialists, a group optometry practice in West Palm Beach, Florida. Dr. Jasper is the Chief Optometric Editor of Optometric Management magazine. She is the Director of Education for Optometric Management Education, where she shares her passion for practice management, customer service, ocular disease, and using new technology to enhance patient care and personal growth. She has experience in almost every mode of optometric practice from her VAMC residency, teaching ocular disease at NEWNCO and Benedict Professor of practice management at Houston College of Optometry, and as a 6-year leaseholder with Walmart. She is a fellow of the American Academy of Optometry and Past-President of the Florida Optometric Association. Stephen M. Montaquila, OD, FAAO, is the owner of West Bay Eye Associates in Warwick, RI. In addition to clinical practice, he is active in research for ocular therapeutics and medical devices and lectures nationally on topics relating to eye health, contact lenses, and practice management. Dr. Montaquila is a Fellow in the American Academy of Optometry and a Diplomate of the American Board of Optometry. He is the past president of the Rhode Island Optometric Association. He has served as a clinical examiner for the National Board of Examiners in Optometry and as adjunct faculty at the Massachusetts College of Pharmacy and Health Sciences. Additionally, he serves as Chair of Rhode Island Primary Care Physicians Corporation Eye Care Group. He is the immediate past Chair of the American Optometric Association Third Party Executive Committee and currently serves on the AOA Federal Relations Committee, where he works nationally with eye care coverage, reimbursement, and policy issues. Nathan M. Radcliffe, MD, is an Associate Clinical Professor of Ophthalmology at Mount Sinai School of Medicine. He is an educator, enthusiast, and early adopter of interventional glaucoma approaches, including laser, drug delivery, and micro-invasive glaucoma surgery (MIGS). He is the Director of the Glaucoma Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS) and is the Glaucoma Day course co-director. He has published extensively in the peer-reviewed literature and is the Chief Medical Editor of the Glaucoma Physician publication. He has treated glaucoma patients in New York City and the Bronx for 14 years. I. Paul Singh, MD, President of The Eye Centers of Racine & Kenosha, Ltd., was named America’s Best Eye Doctor in 2021 by Newsweek. Dr. Singh is passionate about new technology and maintains a full-time research facility where he researches glaucoma, cataract, ocular surface disease, and retina. He was the first surgeon in Wisconsin to perform many MIGS, and the first to use newer in-office YAG lasers to perform YAG Vireolysis. He was instrumental in bringing laser-assisted cataract surgery to the area. He has been published in several ophthalmology journals and presented his research at national meetings and universities worldwide. Dagny Zhu, MD, is a nationally acclaimed, board-certified ophthalmologist and fellowship-trained cornea, cataract, and laser refractive surgery specialist. As a key opinion leader in laser vision correction and premium cataract surgery, Dr. Zhu serves on the editorial board of major ophthalmology publications, lectures to peers worldwide, and leads cutting-edge clinical research studies on the latest presbyopia treatments. She holds leadership positions in the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. She is a member of the prestigious AECOS and Cedars Aspens societies. Dr. Zhu was most recently named a “Top Doctor” by Castle Connolly, “Rising Star in Ophthalmology” by Super Doctors, “Top 50 Global KOL” by MediaMice, “Top 40 under 40” by Ophthalmology Management, and “Outstanding Female Leader” by Millennial Eye. The Radius XR diagnostics platform, which brings together medical-grade diagnostics, business management, and patient education tools in a single wearable device, was named a CES® 2023 Innovation Awards Honoree in both the Digital Health and Virtual & Augmented Reality categories. The entire Radius Scientific Advisory Board is listed on the company’s website at radiusxr.com/science. ### About Radius XR ( www.RadiusXR.com ) The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a wearable XR device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, it adapts to responses to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision. Radius builds on the therapeutic legacy of IrisVision, the first clinically validated wearable low-vision solution. IrisVision was backed by a research grant from the National Eye Institute and developed in collaboration with researchers from top ophthalmology centers at Johns Hopkins University, Stanford University, and UPMC Pittsburg. Contact Details Radius John Trefethen, Chief of Product and Marketing +1 800-607-6222 media@radiusxr.com Company Website https://www.radiusxr.com

May 16, 2023 08:04 AM Pacific Daylight Time